Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Jubilant Pharmova's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a Buyback Yield % of 0.00 as of Aug. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jubilant Pharmova and its competitors. According to the industry distribution chart, Jubilant Pharmova ranks #999999 out of 271 companies in the Drug Manufacturers industry.
Is Jubilant Pharmova's Buyback Yield % too high?
Jubilant Pharmova's current Buyback Yield % is 0.00. Based on the distribution chart, Jubilant Pharmova ranks #999999 out of 271 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jubilant Pharmova has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #999999 out of 271 companies for Buyback Yield %. This places Jubilant Pharmova in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jubilant Pharmova and its competitors. Jubilant Pharmova's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,082.26, compared to a current price of ₹887.10 — trading 18% below its estimated fair value. The current Buyback Yield % is 0.00. Jubilant Pharmova's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Buyback Yield % is 0.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹887.10 is trading 18% below its estimated GF Value™ of ₹1,082.26.
GuruFocus considers Jubilant Pharmova to be Modestly Undervalued.
Key valuation signals for BOM:530019:
Buyback Yield %: 0.00
GF Value™: ₹1,082.26 vs. price of ₹887.10 (18% below fair value)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
73GF Score
Get the complete analysis for BOM:530019
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
